Structure Therapeutics (GPCR) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 24.3% versus a loss of 9.8%. Xeris Biopharma is the larger company by market cap ($1.86 billion vs $1.83 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | XERS |
|---|---|---|
| Share price | $25.67 | $10.19 |
| Market cap | $1.83B | $1.86B |
| 1-day change | -3.79% | +0.79% |
| YTD return | -63.09% | +29.81% |
| 1-year return | -9.77% | +24.27% |
| 5-year return | — | +409.50% |
| Forward P/E | — | 27.54 |
| EPS (TTM) | $-3.03 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | $-141.20M | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $94.90 | $11.33 |
| 52-week low | $25.09 | $5.25 |
| Distance from 52-week high | -72.95% | -10.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +312.08% | +26.20% |
| Average volume | 965.00K | 2.17M |
| Shares outstanding | 71.31M | 182.32M |
| Employees | 281 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed GPCR by 34.0 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
GPCR vs XERS FAQ
Which is bigger, Structure Therapeutics or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.86B compared with $1.83B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, GPCR or XERS?
XERS returned +24.27% over the past 12 months, compared with -9.77% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.